Clinical Trials Arena April 26, 2024
The Series B extension proceeds will fund Phase III trial for Cerevance’s lead CNS therapy, CVN424, in patients with Parkinson’s disease.
US-based Cerevance has secured $47m in Series B-1 extension funding to finance the upcoming Phase III trial for its lead therapy, CVN424.
The financiers included multiple US-based venture capital firms such as Google Ventures, Agent Capital, Bioluminescence Ventures, and Double Point Ventures.
CVN424 is a non-dopamine therapy that inhibits G protein-coupled receptor 6 (GPR6), which is an orphan receptor as it has no naturally produced agonist that activates the receptor. The GPR6 inhibition can potentially improve motor and non-motor manifestations of Parkinson’s. The drug was discovered using Cerevance’s NETSseq (Nuclear Enriched Transcript Sort sequencing) platform.
CVN424 is being evaluated...
Today's Sponsors
Today's Sponsor